Respiratory Strategic Roundup exploring Developments and Competitive Shifts
Coverage Period: 31 July – 3 September 2026
Introduction
The defining story of the respiratory market during this reporting period was the acceleration of competition in idiopathic pulmonary fibrosis (IPF), as multiple late-stage programs moved closer to challenging the current treatment paradigm through differentiated mechanisms, delivery approaches and comparative evidence strategies.
While IPF drove the strongest strategic activity, the broader respiratory landscape also showed a shift toward more targeted market positioning. RSV prevention developers are expanding beyond first-season infant protection, COPD researchers are pursuing mechanisms aimed at underserved inflammatory pathways, and established inhaled therapy players are competing through formulation and device innovation. The market direction is becoming less about adding incremental options and more about demonstrating meaningful clinical differentiation within specific patient populations.
Executive Summary
- IPF competition is entering a new phase as developers pursue differentiated clinical positions rather than incremental antifibrotic additions. United Therapeutics’ FDA acceptance of nebulized Tyvaso, Celea Therapeutics’ head-to-head Phase 3 SURPASS-IPF strategy for deupirfenidone, and Rein Therapeutics’ Fast Track designation for LTI-03 highlight increasing competition around efficacy, delivery, tolerability and potential disease modification.
- Late-stage evidence generation is becoming a key competitive advantage in rare and progressive respiratory diseases. Grifols’ SPARTA Phase 3 study completion in alpha-1 antitrypsin deficiency creates an important upcoming evidence catalyst, while the company’s parallel subcutaneous development program reflects continued efforts to improve treatment options in underserved populations.
- RSV prevention is evolving from a single-season infant market into a broader lifecycle prevention opportunity. Merck’s regulatory submissions for second-season protection with ENFLONSIA and SK bioscience’s pediatric development of RSM01 demonstrate growing competition across antibody-based prevention platforms.
- Respiratory innovation is expanding beyond established treatment categories through new mechanisms and delivery strategies. Fosun Pharma’s DPP-1 inhibitor program in COPD and Chiesi’s expanded single-inhaler triple therapy portfolio reflect continued efforts to address unmet needs through targeted biology and improved treatment flexibility.
Watch the video summary
Strategic Perspective on the Latest Respiratory Market Trends
Idiopathic Pulmonary Fibrosis Competition Shifts Toward Differentiated Evidence, Delivery and Mechanism
IPF emerged as the most strategically important area during the period because several programs are attempting to redefine how treatment value is measured in a disease where current therapies slow progression but do not reverse fibrosis.
United Therapeutics’ FDA acceptance of its supplemental application for nebulized Tyvaso represents one of the most advanced challenges to the current treatment landscape. Supported by positive Phase 3 TETON-1 and TETON-2 data, the program introduces an inhaled approach designed to provide direct lung delivery while targeting multiple disease pathways. If approved, it could create a new competitive dimension beyond the existing oral antifibrotic market.
Celea Therapeutics is pursuing differentiation through comparative evidence. Its SURPASS-IPF Phase 3 study is designed as a head-to-head trial comparing deupirfenidone with pirfenidone, while also incorporating patient-reported outcomes and evaluating potential use alongside existing treatment approaches. This design reflects a growing expectation that future IPF entrants may need to demonstrate advantages against available therapies rather than only placebo-controlled efficacy.
Rein Therapeutics represents an earlier-stage approach focused on fibrosis biology and tissue repair. FDA Fast Track designation for LTI-03 supports continued development interest in therapies that may address mechanisms beyond slowing decline, although the clinical significance of this approach remains dependent on upcoming Phase 2 data.
Market Implication: IPF competition may increasingly be determined by measurable differentiation in clinical outcomes, patient experience, administration and compatibility with existing treatment pathways.
Key Uncertainty: It remains unclear whether emerging therapies can demonstrate advantages large enough to change prescribing behavior in a market with established antifibrotic standards.
COPD Innovation Targets Untreated Inflammatory Pathways and Disease Subgroups
COPD development continues to move beyond broad symptom management toward therapies designed around specific biological drivers of disease.
Fosun Pharma’s Phase 2 development of FXS7553 illustrates this shift. The oral DPP-1 inhibitor is designed to reduce neutrophilic inflammatory responses by inhibiting activation of neutrophil serine proteases. This approach targets a major COPD inflammatory phenotype that has historically lacked mechanism-specific treatment options.
The program is also being studied in non-cystic fibrosis bronchiectasis, suggesting potential relevance across multiple respiratory conditions where neutrophilic inflammation plays a central role.
In alpha-1 antitrypsin deficiency, Grifols completed follow-up in the SPARTA Phase 3 study of Prolastin-C, generating what the company describes as the largest randomized controlled study of augmentation therapy in alpha-1 emphysema to date. The trial’s use of CT densitometry as an endpoint is intended to provide evidence on whether treatment can slow lung tissue loss. Results expected later in 2026 could influence understanding of long-term augmentation therapy value.
Market Implication: Respiratory development is becoming more biologically segmented, creating opportunities for therapies aimed at defined patient groups rather than broad disease categories.
Key Uncertainty: The ability to translate biological rationale into clinically meaningful benefit remains the central challenge for emerging COPD and rare respiratory approaches.
RSV Prevention Expands Toward Broader Protection Windows and Platform Competition
RSV prevention is moving beyond protecting infants during their first RSV season toward longer-duration strategies for children who remain vulnerable after initial protection.
Merck’s regulatory submissions for ENFLONSIA seek to expand use into a second RSV season for children under two years of age at increased risk of severe disease. The applications are supported by Phase 3 SMART trial data and reflect efforts to extend the commercial and clinical role of long-acting antibody prevention.
At the same time, SK bioscience is advancing RSM01, an RSV preventive antibody candidate licensed from the Gates Medical Research Institute, into pediatric Phase 1b development. The program represents an expansion of SK bioscience’s infectious disease strategy beyond vaccines into antibody-based prevention.
The competitive environment may increasingly depend on the ability to address different patient groups, simplify administration and establish global access pathways.
Market Implication: RSV prevention is developing into a broader platform market where lifecycle coverage and technology flexibility may influence long-term positioning.
Key Uncertainty: Regulatory outcomes, reimbursement decisions and real-world adoption will determine how many preventive approaches can achieve meaningful market penetration.
Inhaled Respiratory Therapy Competition Continues Through Formulation and Device Innovation
Respiratory innovation is not limited to new molecules. Established companies continue to compete through delivery systems, formulation improvements and expanded treatment choice.
Chiesi’s European authorization of its single-inhaler triple therapy delivered through the NEXThaler device expands its asthma portfolio for adults whose disease remains uncontrolled on dual therapy. The approval strengthens Chiesi’s position in inhaled respiratory care while also supporting its broader strategy around lower-carbon inhaler technologies.
The commercial impact will depend on national reimbursement decisions and physician adoption, as regulatory approval does not automatically translate into market uptake across European healthcare systems.
Market Implication: Device differentiation and treatment flexibility remain important competitive factors, particularly in chronic respiratory diseases where adherence and usability influence outcomes.
Key Uncertainty: It remains uncertain how much commercial differentiation improved delivery options can create in markets with established inhaled treatment choices.
Next Respiratory Strategic Watchpoints
- FDA review progress for nebulized Tyvaso in IPF and upcoming clinical milestones from SURPASS-IPF and LTI-03 will help determine whether new approaches can meaningfully challenge current antifibrotic treatment expectations.
- Topline SPARTA results from Grifols will provide important evidence on the role of augmentation therapy in alpha-1 antitrypsin deficiency and the value of CT-based disease progression measures.
- Regulatory decisions on ENFLONSIA’s second-season RSV indication will indicate how quickly prevention strategies expand beyond first-season infant protection.
- Early clinical progress for SK bioscience’s RSM01 and Fosun Pharma’s FXS7553 will provide early signals on the viability of antibody-based prevention platforms and neutrophil-targeted COPD approaches.
Respiratory Strategic Roundup: Key Takeaway
The respiratory market is moving toward a more competitive environment where success will depend on proving meaningful differentiation rather than simply entering established categories. IPF represents the clearest example, with developers pursuing new mechanisms, inhaled delivery and comparative trials designed to challenge current standards. Similar shifts are emerging in RSV prevention, COPD and asthma, where treatment strategies are becoming more targeted around biology, patient segments and real-world usability. The next stage of respiratory competition will likely be shaped by the strength of evidence supporting a clear clinical and commercial role.
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Find more Strategic Roundups for multiple therapy areas here.
Contact us at: info@lqventures.com